$4550
The mid-size pharmaceutical market is expected to grow from US$ 690,105.2 million in 2022 to US$ 1,000,584.3 million by 2028; it is estimated to grow at a CAGR of 6.4% from 2022 to 2028.
Revenue, therapy area, R&D expenditure, and reach are among the critical segments of the global pharmaceutical industry. Mid-size pharmaceutical is among the three categories of the pharmaceutical industry. It emphasizes the development of generic drugs and the development of rare disease therapies. The mid-sized pharmaceutical companies have their revenue in the range of US$ 1 billion to US$ 10 billion. The increasing prevalence of chronic diseases, rapidly rising elderly population, and the surging number of products launches and approvals is expected to aid the mid-size pharmaceutical market growth.
The report provides insights and in-depth analysis of the mid-size pharmaceutical market, emphasizing various parameters such as market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players and the impact of the COVID-19 pandemic on the market across all major regions. The COVID-19 pandemic affected three main aspects of the global economy—manufacturing, supply chain, and financial markets. However, the pandemic impact on the mid-size pharmaceutical market was initially negative, which became positive later. In the beginning of the COVID-19 pandemic, the mid-size pharmaceutical market in the regions faced numerous short-term and long-term challenges, including direct impacts on productions and demands, financial impacts on manufacturing companies, and disruptions in supply chain and markets. In mid-size pharmaceutical markets, the effects of the pandemic were nearly predictable. The result was extremely high demand and funding for products essential to the care and treatment of patients, such as vaccines for infectious diseases, respiratory diseases, diabetes, and influenza. However, budgets for nonessential drugs were limited or unavailable.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Mid-Size Pharmaceutical Market: Strategic Insights
Market Size Value in US$ 690,105.2 Million in 2022 Market Size Value by US$ 1,000,584.3 Million by 2028 Growth rate CAGR of 6.4% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2022
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Mid-Size Pharmaceutical Market: Strategic Insights
| Market Size Value in | US$ 690,105.2 Million in 2022 |
| Market Size Value by | US$ 1,000,584.3 Million by 2028 |
| Growth rate | CAGR of 6.4% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Since, the regions have quickly changed trial management, most can deliver the clinical trial services as per clients’ needs. Biotech companies are currently initiating clinical trials in the regions. Since the initial outbreak, the situation in Asia Pacific has improved. As of May 2020, 97% of the sites reopened for patient visits, and 83% of the sites are open for on-site CRA visits. Moreover, hospitals in China are 90% open for inpatient/outpatient visits compared to previous years. Also, clinical sites are returning to normal operations.
Based on region, the mid-size pharmaceutical market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.
Lucrative Regions for Mid-Size Pharmaceutical Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Market Insights
Increasing Prevalence of Chronic Disorders Drives Mid-Size Pharmaceutical Market
Increasing Prevalence of Chronic Disorders Drives Mid-Size Pharmaceutical Market
The aging population and changing social behavior contribute to the steady increase in common and costly long-term health problems. With the accelerating urbanization, people are adopting a sedentary lifestyle, which boosts the rates of obesity and cases of illnesses, such as diabetes. According to the World Health Organization, the prevalence of chronic diseases is projected to increase by 57% by 2026. Increasing demand for health care systems due to the rising incidence of chronic illnesses has become a major concern. For instance, according to the International Diabetes Federation (IDF), the number of people with diabetes in North America was about 46 million in 2019 and is projected to increase to 62 million by 2045. The increase in disease prevalence would be about 35% during the predicted period. Pandemics exert periodic and enormous disruptive strains on fitness systems. Healthcare establishments across the world want to be geared up to collectively comprise outbreaks once they occur. Thus, the increasing prevalence of chronic disorders boosts the mid-size pharmaceutical market growth.
Type-Based Insights
Based on type, the mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share. It is expected to be one of the fastest-growing segments. The market growth for the segment is attributed to the increasing budget allocation by pharmaceutical companies for drugs marketing and higher disposable income.
Mid-Size Pharmaceutical Market, by Type – 2022 and 2028
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Drug Development Type-Based Insights
Based on drug development type, the mid-size pharmaceutical market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022. Increasing demand for contract development and manufacturing organizations (CDMOs) and the rising number of new entrants in the market would propel the market growth for the outsource segment during the forecast period.
Formulation-Based Insights
Based on formulation, the mid-size pharmaceutical market is segmented into tablets & capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022. The wide usage of tablets and capsules in long-term treatments, easy use of sprays, and innovative injectable formulations, such as prefilled and fixed doses syringes, are anticipated to propel the growth of the market for the tablets & capsules segment during the forecast period.
Therapy Class-Based Insights
Based on therapy class, the mid-size pharmaceutical market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022. Owing to the rising prevalence of chronic diseases and the growing incidence of cancer, the market for the cancer segment is anticipated to grow rapidly during the forecast period.
The mid-size pharmaceutical market players are adopting organic and inorganic strategies, including product launch and expansion, to expand their footprint and product portfolio globally. DAIICHI SANKYO COMPANY, LIMITED; Eisai Co., Ltd.; Regeneron Pharmaceuticals, Inc; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Ltd; Alexion Pharmaceuticals, Inc.; Mallinckrodt; Endo Pharmaceuticals Inc.; Les Laboratories Servier; and UCB S.A. are among the leading companies in the mid-size pharmaceutical market.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Drug Development Type, Formulation, and Therapy Class
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
DAIICHI SANKYO COMPANY LIMITED and Regeneron Pharmaceuticals, Inc, are the top two companies that hold huge market shares in the mid-size pharmaceuticals market.
The mid-size pharmaceuticals market majorly consists of players such as DAIICHI SANKYO COMPANY LIMITED, Eisai Co., Ltd., Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Alexion Pharmaceuticals, Inc., Mallinckrodt, Endo Pharmaceuticals Inc., Les Laboratories Servier, UCB S.A. amongst others.
In 2021, the hip outsource held the largest share of the market, by drug development type. It is expected to report a higher CAGR of 6.7% during 2021–2028.
In 2021, the over-the-counter segment accounted for the largest share of the market; it is further expected to continue its dominance over the forecast period. The major driving factors for the growth of the over-the-counter segment are increasing budget allocation by pharmaceutical companies for the marketing of drugs, higher disposable income, and the rising prevalence of chronic diseases. Moreover, the increasing self-medication tendency among the population is one of the significant factors in the growth of the over-the-counter (OTC) segment.
The CAGR value of the mid-size pharmaceuticals market during the forecasted period of 2021–2028 is 6.4%.
Key factors that are driving the growth of this market are the growing prevalence of prevalence of chronic disorders and rising number of product launches and approvals are expected to drive the market during the forecast period.
Mid-size pharmaceutical is among the three categories of pharmaceutical industry. The global pharmaceutical industry is segmented on the basis of their revenue, therapy area, R&D expenditure, reach etc. The mid-sized pharmaceutical companies are those companies which have their revenue in range of US$ 1 billion to US$ 10 billion. Mid-size pharmaceutical emphasizes on generic drug and development of rare disease therapies.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Mid-Size Pharmaceutical – By Type
1.3.2 Global Mid-Size Pharmaceutical – By Drug Development Type
1.3.3 Global Mid-Size Pharmaceutical – By Formulation
1.3.4 Global Mid-Size Pharmaceutical – By Therapy Area
1.3.5 Global Mid-Size Pharmaceutical – By Geography
2. Mid-Size Pharmaceutical– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Mid-Size Pharmaceutical – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East & Africa – PEST Analysis
4.2.5 South & Central America – PEST Analysis
4.3 Expert Opinion
5. Mid-Size Pharmaceutical Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Disorders
5.1.2 Increasing Product Approval and Launches
5.2 Market Restraints
5.2.1 Cutthroat Competition among Market Players
5.3 Market Opportunities
5.3.1 Rising Number of Healthcare Start-ups
5.4 Future Trends
5.4.1 Greater Focus on R&D
5.5 Impact Analysis
6. Mid-Size Pharmaceutical Market– Global Analysis
6.1 Global Mid-Size Pharmaceutical Market Revenue Forecast And Analysis
6.1.1 Global Mid-Size Pharmaceutical Market Revenue Forecast And Analysis
6.1.2 Global Mid-Size Pharmaceutical Market – Market Potential Analysis, By Region
6.2 Market Positioning Analysis Of Key Players In Mid-Size Pharmaceutical Market
6.2.1 Company Analysis
6.2.2 Growth Strategy Analysis
6.2.3 Performance Of Key Players
6.2.3.1 Regeneron Pharmaceuticals, Inc.
6.2.3.2 DAIICHI SANKYO COMPANY LIMITED
7. Global Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028– by Type
7.1 Overview
7.2 Mid-Size Pharmaceutical Market Revenue Share, by Type (2022 and 2028)
7.3 Prescription
7.3.1 Overview
7.3.2 Prescription: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Over-the-Counter (OTC)
7.4.1 Overview
7.4.2 Over-the-Counter: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
8. Mid-Size Pharmaceutical Market Analysis – By Drug Development Type
8.1 Overview
8.2 Mid-Size Pharmaceutical Market Revenue Share, by Drug Development Type (2022 and 2028)
8.3 In-House
8.3.1 Overview
8.3.2 In-House: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Outsource
8.4.1 Overview
8.4.2 Outsource: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
9. Mid-Size Pharmaceutical Market – By Formulation
9.1 Overview
9.2 Mid-Size Pharmaceutical Market, by Formulation, 2022 and 2028 (%)
9.3 Tablets and Capsules
9.3.1 Overview
9.3.2 Tablets and Capsules: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Injectables
9.4.1 Overview
9.4.2 Injectables: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Sprays
9.5.1 Overview
9.5.2 Sprays: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Other Formulations
9.6.1 Overview
9.6.2 Others: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
10. Mid-Size Pharmaceutical Market – By Therapy Class
10.1 Overview
10.2 Mid-Size Pharmaceutical Market, by Therapy Class, 2022 and 2028 (%)
10.3 Cardiovascular Diseases
10.3.1 Overview
10.3.2 Cardiovascular Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Pain Management
10.4.1 Overview
10.4.2 Pain Management: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Diabetes
10.5.1 Overview
10.5.2 Diabetes: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Cancer
10.6.1 Overview
10.6.2 Cancer: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
10.7 Other Diseases
10.7.1 Overview
10.7.2 Other Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11. Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 – Geographical Analysis
11.1 North America: Mid-Size Pharmaceutical Market
11.1.1 Overview
11.1.2 North America: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3 North America: Mid-Size Pharmaceutical Market, by Type, 2019–2028 (US$ Million)
11.1.4 North America: Mid-Size Pharmaceutical Market, by Drug Development Type, 2019–2028 (US$ Million)
11.1.5 North America: Mid-Size Pharmaceutical Market, by Formulation, 2019–2028 (US$ Million)
11.1.6 North America: Mid-Size Pharmaceutical Market, by Therapy Area, 2019–2028 (US$ Million)
11.1.7 North America: Mid-Size Pharmaceutical Market, by Country, 2021 & 2028 (%)
11.1.7.1 US: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.1.1 Overview
11.1.7.1.2 US: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.1.3 US: Mid-Size Pharmaceutical Market, by Type, 2019–2028 (US$ Million)
11.1.7.1.4 US: Mid-Size Pharmaceutical Market, by Drug Development Type, 2019–2028 (US$ Million)
11.1.7.1.5 US: Mid-Size Pharmaceutical Market, by Formulation, 2019–2028 (US$ Million)
11.1.7.1.6 US: Mid-Size Pharmaceutical Market, by Therapy Area, 2019–2028 (US$ Million)
11.1.7.2 Canada: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.2.1 Overview
11.1.7.2.2 Canada: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.2.3 Canada: Mid-Size Pharmaceutical Market, by Type, 2019–2028 (US$ Million)
11.1.7.2.4 Canada: Mid-Size Pharmaceutical Market, by Drug Development Type, 2019–2028 (US$ Million)
11.1.7.2.5 Canada: Mid-Size Pharmaceutical Market, by Formulation, 2019–2028 (US$ Million)
11.1.7.2.6 Canada: Mid-Size Pharmaceutical Market, by Therapy Area, 2019–2028 (US$ Million)
11.1.7.3 Mexico: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.3.1 Overview
11.1.7.3.2 Mexico: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.3.3 Mexico: Mid-Size Pharmaceutical Market, by Type, 2019–2028 (US$ Million)
11.1.7.3.4 Mexico: Mid-Size Pharmaceutical Market, by Drug Development Type, 2019–2028 (US$ Million)
11.1.7.3.5 Mexico: Mid-Size Pharmaceutical Market, by Formulation, 2019–2028 (US$ Million)
11.1.7.3.6 Mexico: Mid-Size Pharmaceutical Market, by Therapy Area, 2019–2028 (US$ Million)
11.2 Europe: Mid-Size Pharmaceutical Market
11.2.1 Overview
11.2.2 Europe: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.3 Europe: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
11.2.4 Europe: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
11.2.4.1 Europe: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.2.4.2 Europe: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.2.5 Europe: Mid-Size Pharmaceutical Market, by Country, 2021 & 2028 (%)
11.2.5.1 Germany: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.1.1 Overview
11.2.5.1.2 Germany: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.1.3 Germany: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
11.2.5.1.4 Germany: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
11.2.5.1.5 Germany: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.2.5.1.6 Germany: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.2.5.2 France: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.2.1 Overview
11.2.5.2.2 France: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.2.3 France: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
11.2.5.2.4 France: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
11.2.5.2.5 France: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.2.5.2.6 France: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.2.5.3 UK: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.3.1 Overview
11.2.5.3.2 UK: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.3.3 UK: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
11.2.5.3.4 UK: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
11.2.5.3.5 UK: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.2.5.3.6 UK: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.2.5.4 Italy: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.4.1 Overview
11.2.5.4.2 Italy: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.4.3 Italy: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
11.2.5.4.4 Italy: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
11.2.5.4.5 Italy: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.2.5.4.6 Italy: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.2.5.5 Spain: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.5.1 Overview
11.2.5.5.2 Spain: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.5.3 Spain: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
11.2.5.5.4 Spain: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
11.2.5.5.5 Spain: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.2.5.5.6 Spain: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.2.5.6 Rest of Europe: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.6.1 Overview
11.2.5.6.2 Rest of Europe: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
11.2.5.6.3 Rest of Europe: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
11.2.5.6.4 Rest of Europe: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
11.2.5.6.5 Rest of Europe: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.2.5.6.6 Rest of Europe: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.3 Asia Pacific: Mid-Size Pharmaceutical Market
11.3.1 Overview
11.3.2 Asia Pacific: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (USD Million)
11.3.3 Asia Pacific: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)
11.3.3.1 Asia Pacific: Mid-Size Pharmaceutical Market, By Drug Development Type, 2019–2028 (USD Million)
11.3.3.2 Asia Pacific: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)
11.3.4 Asia Pacific: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)
11.3.5 Asia Pacific: Mid-Size Pharmaceutical Market, by Country, 2022 & 2028 (%)
11.3.5.1 China: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.1.1 China: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.1.2 China: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)
11.3.5.1.3 China: Mid-Size Pharmaceutical Market, By Drug Development Type, 2019–2028 (USD Million)
11.3.5.1.4 China: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)
11.3.5.1.5 China: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)
11.3.5.2 Japan: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.2.1 Japan: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.2.2 Japan: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)
11.3.5.2.3 Japan: Mid-Size Pharmaceutical Market, By Drug Development Type , 2019–2028 (USD Million)
11.3.5.2.4 Japan: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)
11.3.5.2.5 Japan: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)
11.3.5.3 India: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.3.1 India: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.3.2 India: Mid-Size Pharmaceutical Market, By Type , 2019–2028 (USD Million)
11.3.5.3.3 India: Mid-Size Pharmaceutical Market, By Drug Development Type, 2019–2028 (USD Million)
11.3.5.3.4 India: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)
11.3.5.3.5 India: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)
11.3.5.4 Australia: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.4.1 Australia: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.4.2 Australia: Mid-Size Pharmaceutical Market , By Type , 2019–2028 (USD Million)
11.3.5.4.3 Australia: Mid-Size Pharmaceutical Market , By Drug Development Type , 2019–2028 (USD Million)
11.3.5.4.4 Australia: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)
11.3.5.4.5 Australia: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)
11.3.5.5 South Korea: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.5.1 South Korea: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.5.2 South Korea: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)
11.3.5.5.3 South Korea: Mid-Size Pharmaceutical Market, By Drug Development Type , 2019–2028 (USD Million)
11.3.5.5.4 South Korea: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)
11.3.5.5.5 South Korea: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)
11.3.5.6 Rest of Asia Pacific: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.6.1 Rest of Asia Pacific: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.3.5.6.2 Rest of Asia Pacific: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)
11.3.5.6.3 Rest of Asia Pacific: Mid-Size Pharmaceutical Market, By Drug Development Type, 2019–2028 (USD Million)
11.3.5.6.4 Rest of Asia Pacific: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)
11.3.5.6.5 Rest of Asia Pacific: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)
11.4 Middle East & Africa Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028
11.4.1 Overview
11.4.2 Middle East & Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.3 Middle East & Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.4.4 Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)
11.4.4.1 Middle East & Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.4.4.2 Middle East & Africa: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.4.5 Middle East & Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Country (%)
11.4.5.1 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.5.1.1 Overview
11.4.5.1.2 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.5.1.3 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.4.5.1.4 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)
11.4.5.1.5 UAE: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.4.5.1.6 UAE: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.4.5.2 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.5.2.1 Overview
11.4.5.2.2 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.5.2.3 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.4.5.2.4 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)
11.4.5.2.5 Saudi Arabia: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.4.5.2.6 Saudi Arabia: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.4.5.3 South Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.5.3.1 Overview
11.4.5.3.2 South Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.5.3.3 South Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.4.5.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)
11.4.5.3.5 South Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.4.5.3.6 South Africa: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
11.4.5.4 Rest of Middle East and Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.5.4.1 Overview
11.4.5.4.2 Rest of Middle East and Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.4.5.4.3 Rest of Middle East & Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.4.5.4.4 Rest of Middle East & Africa: Metabolomics Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)
11.4.5.4.5 Rest of Middle East and Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.4.5.4.6 Rest of Middle East and Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
11.5 South & Central America: Mid-Size Pharmaceutical Market
11.5.1 Overview
11.5.2 South and Central America: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.5.3 South and Central America: Mid-Size Pharmaceutical Market, by Type, 2019–2028 (USD Million)
11.5.4 South and Central America: Mid-Size Pharmaceutical Market, by Drug Development Type, 2019–2028 (USD Million)
11.5.5 South and Central America: Mid-Size Pharmaceutical Market, by Formulation, 2019–2028 (USD Million)
11.5.6 South and Central America: Mid-Size Pharmaceutical Market, by Therapy Area, 2019–2028 (USD Million)
11.5.7 South and Central America: Mid-Size Pharmaceutical Market, by country, 2021 & 2028 (%)
11.5.7.1 Brazil: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.5.7.1.1 Brazil: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.5.7.1.2 Brazil: Mid-Size Pharmaceutical Market, by Type, 2019–2028 (USD Million)
11.5.7.1.3 Brazil: Mid-Size Pharmaceutical Market, by Drug Development Type, 2019–2028 (USD Million)
11.5.7.1.4 Brazil: Mid-Size Pharmaceutical Market, by Formulation, 2019–2028 (USD Million)
11.5.7.1.5 Brazil: Mid-Size Pharmaceutical Market, by Therapy Area, 2019–2028 (USD Million)
11.5.7.2 Argentina: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.5.7.2.1 Argentina: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.5.7.2.2 Argentina: Mid-Size Pharmaceutical Market, by Type, 2019–2028 (USD Million)
11.5.7.2.3 Argentina: Mid-Size Pharmaceutical Market, by Drug Development Type, 2019–2028 (USD Million)
11.5.7.2.4 Argentina: Mid-Size Pharmaceutical Market, by Formulation, 2019–2028 (USD Million)
11.5.7.2.5 Argentina: Mid-Size Pharmaceutical Market, by Therapy Area, 2019–2028 (USD Million)
11.5.7.3 Rest of South and Central America: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.5.7.3.1 Rest of South and Central America: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
11.5.7.3.2 Rest of South and Central America: Mid-Size Pharmaceutical Market, by Type, 2019–2028 (USD Million)
11.5.7.3.3 Rest of South and Central America: Mid-Size Pharmaceutical Market, by Drug Development Type, 2019–2028 (USD Million)
11.5.7.3.4 Rest of South and Central America: Mid-Size Pharmaceutical Market, by Formulation, 2019–2028 (USD Million)
11.5.7.3.5 Rest of South and Central America: Mid-Size Pharmaceutical Market, by Therapy Area, 2019–2028 (USD Million)
12. Impact Of COVID-19 Pandemic on Mid-Size Pharmaceutical Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
12.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
12.5 South and Central America: Impact Assessment of COVID-19 Pandemic
13. Mid-Size Pharmaceutical Market–Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 DAIICHI SANKYO COMPANY LIMITED
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Eisai Co., Ltd.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Bausch Health Companies Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Regeneron Pharmaceuticals, Inc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Sun Pharmaceutical Industries Ltd
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Alexion Pharmaceuticals, Inc.
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Mallinckrodt
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Endo Pharmaceuticals Inc.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Les Laboratories Servier
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 UCB S.A.
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (USD Million)
Table 3. North America Mid-Size Pharmaceutical Market, by Formulation– Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Mid-Size Pharmaceutical Market, by Therapy Area– Revenue and Forecast to 2028 (US$ Million)
Table 5. US Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. US Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 7. US Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 8. US Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 17. Europe: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Europe: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 19. Europe: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 20. Europe: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 21. Germany: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 22. Germany: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 23. Germany: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 24. Germany: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 25. France: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 26. France: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 27. France: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 28. France: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 29. UK: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 30. UK: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 31. UK: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 32. UK: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 33. Italy: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 34. Italy: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 35. Italy: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 36. Italy: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 37. Spain: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 38. Spain: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 39. Spain: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 40. Spain: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 41. Rest of Europe: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 42. Rest of Europe: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)
Table 43. Rest of Europe: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 44. Rest of Europe: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 45. Asia Pacific: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 46. Asia Pacific: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and forecast to 2028 (USD Million)
Table 47. Asia Pacific: Mid-Size Pharmaceutical Market, By Formulation – Revenue and forecast to 2028 (USD Million)
Table 48. Asia Pacific: Mid-Size Pharmaceutical Market, By Therapy Area – Revenue and Forecast to 2028 (USD Million)
Table 49. China: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 50. China: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and forecast to 2028 (USD Million)
Table 51. China: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)
Table 52. China: Mid-Size Pharmaceutical Market , By Therapy Area– Revenue and Forecast to 2028 (USD Million)
Table 53. Japan: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 54. Japan: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 55. Japan: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)
Table 56. Japan: Mid-Size Pharmaceutical Market , By Therapy Area– Revenue and Forecast to 2028 (USD Million)
Table 57. India: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 58. India: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 59. India: Mid-Size Pharmaceutical Market, By Formulation - Revenue and Forecast to 2028 (USD Million)
Table 60. India: Mid-Size Pharmaceutical Market, By Therapy Area– Revenue and Forecast to 2028 (USD Million)
Table 61. Australia: Mid-Size Pharmaceutical Market , By Type – Revenue and Forecast to 2028 (USD Million)
Table 62. Australia: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 63. Australia: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)
Table 64. Australia: Mid-Size Pharmaceutical Market, By Therapy Area – Revenue and Forecast to 2028 (USD Million)
Table 65. South Korea: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 66. South Korea: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 67. South Korea: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)
Table 68. South Korea: Mid-Size Pharmaceutical Market, By Therapy Area – Revenue and Forecast to 2028 (USD Million)
Table 69. Rest of Asia Pacific: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 70. Rest of Asia Pacific: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 71. Rest of Asia Pacific: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)
Table 72. Rest of Asia Pacific: Mid-Size Pharmaceutical Market, By Therapy Area – Revenue and Forecast to 2028 (USD Million)
Table 73. Middle East & Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 74. Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)
Table 75. Middle East & Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 76. Middle East & Africa: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 77. UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 78. UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)
Table 79. UAE: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 80. UAE: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 81. Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 82. Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)
Table 83. Saudi Arabia: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 84. Saudi Arabia: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 85. South Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 86. South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)
Table 87. South Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 88. South Africa: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)
Table 89. Rest of Middle East & Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 90. Rest of Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)
Table 91. Rest of Middle East and Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 92. Rest of Middle East and Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 93. South and Central America: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 94. South and Central America: Mid-Size Pharmaceutical Market, by Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 95. South and Central America: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (USD Million)
Table 96. South and Central America: Mid-Size Pharmaceutical Market, by Therapy Area– Revenue and Forecast to 2028 (USD Million)
Table 97. Brazil: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 98. Brazil: Mid-Size Pharmaceutical Market, by Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 99. Brazil: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (USD Million)
Table 100. Brazil: Mid-Size Pharmaceutical Market, by Therapy Area– Revenue and Forecast to 2028 (USD Million)
Table 101. Argentina: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 102. Argentina: Mid-Size Pharmaceutical Market, by Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 103. Argentina: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (USD Million)
Table 104. Argentina: Mid-Size Pharmaceutical Market, by Therapy Area– Revenue and Forecast to 2028 (USD Million)
Table 105. Rest of South and Central America: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 106. Rest of South and Central America: Mid-Size Pharmaceutical Market, by Drug Development Type – Revenue and Forecast to 2028 (USD Million)
Table 107. Rest of South and Central America: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (USD Million)
Table 108. Rest of South and Central America: Mid-Size Pharmaceutical Market, by Therapy Area– Revenue and Forecast to 2028 (USD Million)
Table 109. Organic Developments Done By Companies
Table 110. Inorganic Developments Done By Companies
Table 111. Glossary of Terms
LIST OF FIGURES
Figure 1. Mid-Size Pharmaceutical Segmentation
Figure 2. Mid-Size Pharmaceutical Segmentation, By Region
Figure 3. Global Mid-Size Pharmaceutical Overview
Figure 4. Over-the-Counter Segment Held Largest Share by Type in Mid-Size Pharmaceutical Market
Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Global Mid-Size Pharmaceutical, By Geography (US$ Million)
Figure 7. Global Mid-Size Pharmaceutical - Leading Country Markets (US$ Million)
Figure 8. Global Mid-Size Pharmaceutical, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East & Africa: PEST Analysis
Figure 13. South & Central America: PEST Analysis
Figure 14. Global Mid-Size Pharmaceutical Market– Revenue Forecast And Analysis – 2020- 2028
Figure 15. Global Mid-Size Pharmaceutical Market– Revenue Forecast And Analysis – 2021 - 2028
Figure 16. Global Mid-Size Pharmaceutical Market – Market Potential Analysis, By Region
Figure 17. Market Positioning Analysis Of Key Players In Global Mid-Size Pharmaceutical Market
Figure 18. Global Mid-Size Pharmaceutical Market – Comparative Company Analysis
Figure 19. Global Mid-Size Pharmaceutical Market – Growth Strategy Analysis
Figure 20. Mid-Size Pharmaceutical Market Revenue Share, by Type (2022 and 2028)
Figure 21. Prescription: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Over-the-Counter: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Mid-Size Pharmaceutical Market Revenue Share, by Drug Development Type (2022 and 2028)
Figure 24. In-House: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Outsource: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Mid-Size Pharmaceutical Market, by Formulation, 2022 and 2028 (%)
Figure 27. Tablets and Capsules: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Injectables: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Sprays: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Others: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Mid-Size Pharmaceutical Market, by Therapy Class, 2022 and 2028 (%)
Figure 32. Cardiovascular Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Pain Management: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Diabetes: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Cancer: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Other Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. North America: Mid-Size Pharmaceutical Market, by Key Country – Revenue (2022) (US$ Million)
Figure 38. North America Mid-Size Pharmaceutical Market Revenue and Forecast to 2028 (US$ Million)
Figure 39. North America: Mid-Size Pharmaceutical Market, by Country, 2021 & 2028 (%)
Figure 40. US: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Canada: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Mexico: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Europe: Mid-Size Pharmaceutical Market, by Key Country – Revenue (2021) (US$ Million)
Figure 44. Europe: Mid-Size Pharmaceutical Market Revenue and Forecast to 2028 (US$ Million)
Figure 45. Europe: Mid-Size Pharmaceutical Market, by Country, 2021 & 2028 (%)
Figure 46. Germany: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 47. France: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 48. UK: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 49. Italy: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 50. Spain: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 51. Rest of Europe: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)
Figure 52. Asia Pacific Mid-Size Pharmaceutical Market, by Key Country – Revenue (2022) (USD Million)
Figure 53. Asia Pacific Mid-Size Pharmaceutical Market Revenue and Forecast to 2028 (USD Million)
Figure 54. Asia Pacific: Mid-Size Pharmaceutical Market, by Country, 2022 & 2028 (%)
Figure 55. China: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 56. Japan: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 57. India: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 58. Australia: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 59. South Korea: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 60. Rest of Asia Pacific: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 61. Middle East & Africa Mid-Size Pharmaceutical Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 62. Middle East & Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
Figure 63. Middle East & Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Country (%)
Figure 64. UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
Figure 65. Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
Figure 66. South Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
Figure 67. Rest of Middle East and Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
Figure 68. South and Central America: Mid-Size Pharmaceutical Market, by Key Country – Revenue (2022) (US$' Million)
Figure 69. South and Central America Mid-Size Pharmaceutical Market Revenue and Forecast to 2028 (USD Million)
Figure 70. South and Central America: Mid-Size Pharmaceutical Market, by country, 2021 & 2028 (%)
Figure 71. Brazil: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 72. Argentina: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 73. Rest of South and Central America: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)
Figure 74. Impact of COVID-19 Pandemic in North American Country Markets
Figure 75. Impact of COVID-19 Pandemic in European Country Markets
Figure 76. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 77. Impact of COVID-19 Pandemic in Middle East and Africa Country Markets
Figure 78. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 79. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies - Mid-Size Pharmaceutical Market
- DAIICHI SANKYO COMPANY LIMITED
- Eisai Co., Ltd.
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals, Inc
- Sun Pharmaceutical Industries Ltd
- Alexion Pharmaceuticals, Inc.
- Mallinckrodt
- Endo Pharmaceuticals Inc.
- Les Laboratories Servier
- UCB S.A.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jun 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jun 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jun 2022
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)
Jun 2022
Enteral and Parenteral Medical Nutrition Market
Forecast to 2028 - Global Analysis by Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer's Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole–Source), Form (Liquid, Powder, and Semi–Solid), Product Type (General and Disease–Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18–60 Years, 3–18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
Jun 2022
CIN & HR-HPV Treatment Market
Forecast to 2028 - Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)
Jun 2022
Pharmaceutical Fluid Handling Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering (Equipment & Solutions and Services), Tubing (Thermoplastic Elastomers, Polyvinyl Chloride, and Silicone), Application (Fluid Handling & Management, Fluid Preparation, Integration & Automation, Buffer Management, and Others), Usage (Cough Syrup, Intravenous Product, Complex Active Pharmaceutical Ingredients, and Others), and End User (Biotechnology Companies, Pharmaceutical & Medical Companies, and Others)
Jun 2022
Enteral Medical Nutrition Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]
Jun 2022
Glycomic Therapeutics Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]